Alopecia: Clinical Trials

87 completed, 19 recruiting, 19 unknown, 13 not yet recruiting. 171 Phase 2, 33 Phase 1, 13 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	171	Completed 87, Recruiting 19, Unknown 19, Not yet recruiting 13, Terminated 13, Withdrawn 10, Active not recruiting 9, Enrolling by invitation 1
Phase 1	33	Unknown 10, Completed 9, Recruiting 6, Not yet recruiting 3, Terminated 2, Active not recruiting 1, Enrolling by invitation 1, Withdrawn 1
Phase 3	13	Completed 6, Not yet recruiting 3, Active not recruiting 2, Recruiting 1, Unknown 1

Follow Alopecia: new trials by email Literature Review of Alopecia trials Research Report on Alopecia

Trials (filtered) newest first · largest first

All 171 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
XVIE to Treat Androgenetic Alopecia (AGA) Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution - Androgenetic Alopecia	Phase 1 / Phase 2	Not yet recruiting	Restore Biologics Holdings, Inc. dba Xtressé	30	2026-12-01	2026-08-12
Efficacy of Botulinum Toxin A Versus Nanofat in the Treatment of Androgenetic Alopecia: A Comparative Clinical Trial Botulinum Toxin Type A, Autologous Nanofat Injection - Androgenetic Alopecia	Phase 2 / Phase 3	Not yet recruiting	Sherief Ayman Hussein Shaamash	40	2026-12-01	2026-10-07
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia PP405 0.05% Topical Gel, Vehicle Topical Gel - Androgenetic Alopecia	Phase 2	Not yet recruiting	Pelage Pharmaceuticals, Inc.	200	2026-11-01	2026-11-06
Phase 2/3 Efficacy and Safety of PP405 in Adult Males PP405 0.05% Topical Gel, Vehicle Topical Gel - Androgenetic Alopecia	Phase 2 / Phase 3	Recruiting	Pelage Pharmaceuticals, Inc.	600	2026-09-21	2026-10-28
Tirzepatide for Treatment of CCCA Tirzepatide - Central Centrifugal Cicatricial Alopecia (CCCA)	Phase 2	Recruiting	Johns Hopkins University	20	2026-09-15	2026-11-03
Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA) Delgocitinib - Frontal Fibrosing Alopecia	Phase 2	Not yet recruiting	Maryanne Makredes Senna	30	2026-09-10	2026-08-26
SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates scalp cooling, photographs via the Belle.AI app, Antibody-Drug Conjugates - Advanced or Metastatic Solid Tumour, Antibody-Drug Conjugate	Phase 2	Not yet recruiting	Jules Bordet Institute	102	2026-09-01	2026-08-19
Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata Drug: VC005 tablets, VC005 tablets, VC005 placebo tablets - Alopecia Areata	Phase 2	Recruiting	Jiangsu vcare pharmaceutical technology co., LTD	120	2026-08-18	2026-08-27
Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth DA-001, Placebo, Phenylephrine - Telogen Effluvium, Female Pattern Hair Loss	Phase 2 / Phase 3	Not yet recruiting	Applied Biology, Inc.	1120	2026-05-01	2026-04-13
Exosome Therapy for Male Androgenetic Alopecia Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes, Normal Saline (0.9% NaCl) - Androgenetic Alopecia (AGA)	Phase 2	Recruiting	Zhang Han	120	2026-04-30	2026-07-09
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) LY4005130, Placebo - Alopecia Areata	Phase 2	Recruiting	Eli Lilly and Company	65	2026-04-14	2026-11-04
Biologics in Folliculitis Decalvans : an Adaptative Trial Research Adalimumab, Ustekinumab, Baricitinib - Folliculitis Decalvans (FD)	Phase 2	Not yet recruiting	Assistance Publique - Hôpitaux de Paris	120	2026-04-01	2025-12-05
Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia AD-303A, AD-3031 - Androgenetic Alopecia	Phase 1 / Phase 2	Not yet recruiting	Moogene Medi Co., Ltd	30	2026-04-01	2026-03-24
Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia Lactobacillus reuteri, Inactivated Lactobacillus reuteri, 5% Minoxidil - Androgenetic Alopecia (AGA)	Phase 2	Recruiting	Shenzhen People's Hospital	388	2026-01-25	2026-04-01
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome Abrocitinib - Atopic Dermatitis, Alopecia Areata	Phase 2	Recruiting	Icahn School of Medicine at Mount Sinai	56	2026-01-12	2026-10-16
Study of EPI-001 in Patients With Androgenetic Alopecia EPI-001, Placebo - Androgenetic Alopecia	Phase 1 / Phase 2	Recruiting	Epibiotech	42	2026-01-12	2026-06-01
Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients Secretome, Platelet-Rich Plasma (PRP) Injections - Androgenetic Alopecia	Phase 1 / Phase 2	Recruiting	PT. Prodia Stem Cell Indonesia	40	2026-01-09	2026-02-24
PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study Injection of PRP combined with Botulinum Toxin Type A into the alopecic area(s), PRP-only injection into the alopecic area - Androgenetic Alopecia (AGA)	Phase 2	Completed	Nanfang Hospital, Southern Medical University	83	2026-01-09	2026-09-09
A Study of LAD603 in Adults With Alopecia Areata LAD603, Placebo - Alopecia Areata	Phase 2	Recruiting	Almirall, S.A.	136	2025-12-17	2026-05-20
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia OLX72021, Placebo - Androgenetic Alopecia (AGA)	Phase 1 / Phase 2	Recruiting	Olix Pharmaceuticals, Inc.	158	2025-12-04	2026-10-13

Showing 20 of 171. Sign in to see all of them.

Narrower conditions

Alopecia Areata (70)  ·  Alopecia universalis (15)  ·  Dermatitis, Atopic (3)  ·  Hair Diseases (3)  ·  Skin Diseases (3)  ·  Down Syndrome (2)  ·  Hirsutism (2)  ·  Hypotrichosis (2)  ·  Lymphoma, Follicular (2)  ·  Psoriasis (2)  ·  Acne Vulgaris (1)  ·  Autoimmune Diseases (1)  ·  Breast Neoplasms (1)  ·  Dermatitis (1)

Broader conditions

Skin and Connective Tissue Diseases (171)  ·  Hypotrichosis (169)  ·  Hair Diseases (168)  ·  Skin Diseases (168)  ·  Pathological Conditions, Signs and Symptoms (116)  ·  Pathological Conditions, Anatomical (115)  ·  Immune System Diseases (6)  ·  Neoplasms (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Dermatitis (3)  ·  Genetic Diseases, Inborn (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Hypersensitivity (3)  ·  Hypersensitivity, Immediate (3)

Interventions

Minoxidil (19)  ·  Solutions (8)  ·  Finasteride (6)  ·  baricitinib (4)  ·  Abatacept (3)  ·  Bimatoprost (3)  ·  Gels (3)  ·  PF-06651600 (3)  ·  Saline Solution (3)  ·  Sodium Chloride (3)  ·  dupilumab (3)  ·  ruxolitinib (3)  ·  BID protein, human (2)  ·  Ethanol (2)  ·  PF-06700841 (2)

Sponsors

Aderans Research Institute (11)  ·  Aclaris Therapeutics, Inc. (5)  ·  Allergan (4)  ·  Columbia University (4)  ·  Concert Pharmaceuticals (4)  ·  Emma Guttman (4)  ·  Icahn School of Medicine at Mount Sinai (4)  ·  Pfizer (4)  ·  Suzhou Kintor Pharmaceutical Inc, (4)  ·  University of Minnesota (4)  ·  Biosplice Therapeutics, Inc. (3)  ·  Follicum AB (3)  ·  Pelage Pharmaceuticals, Inc. (3)  ·  Eli Lilly and Company (2)  ·  Equillium (2)

Countries

United States (91)  ·  China (20)  ·  Canada (17)  ·  Australia (12)  ·  Germany (11)  ·  South Korea (9)  ·  Egypt (7)  ·  France (5)  ·  Japan (5)  ·  Poland (5)  ·  Pakistan (4)  ·  United Kingdom (4)  ·  India (3)  ·  Spain (3)  ·  Taiwan (3)

Top investigators

Julian Mackay-Wiggan, MD, MS (5)  ·  Emma Guttman-Yassky, MD, PhD (3)  ·  Yusuf Yazici, M.D. (3)  ·  Christina Weng (2)  ·  Emma Guttman, MD (2)  ·  Emma Guttman, MD, PhD (2)  ·  Johannes Gassmueller, MD (2)  ·  Maria K Hordinsky, MD (2)  ·  Rajendarsingh Rajput, Dr. (2)  ·  Reid Waldman, M.D. (2)  ·  Sandeep Sattur, Dr. (2)  ·  Timothy Durso, M.D. (2)

Results publications

PMID 38263353, PMID 41917311, PMID 42481842, PMID 25896390, PMID 28619556, PMID 37917289, PMID 18645136, PMID 19620039, PMID 20115946, PMID 21042071, PMID 21199096, PMID 21712909, PMID 21899919, PMID 22233865, PMID 22833322, PMID 24872229, PMID 25601618, PMID 25676427, PMID 25765294, PMID 27699252, PMID 27699253, PMID 29452121, PMID 29923063, PMID 30113844, PMID 31245963, PMID 31321800, PMID 31574029, PMID 32478930, PMID 34460948, PMID 34863853, PMID 34915057, PMID 35334197, PMID 36045513, PMID 36571611, PMID 36763878, PMID 36855020, PMID 37062298, PMID 37381691, PMID 37403610, PMID 37556146, PMID 37707764, PMID 37991697, PMID 38833144, PMID 38904749, PMID 38946973, PMID 39141364, PMID 39254890, PMID 39328096, PMID 39441519, PMID 39461505

NIH funding

2016 (2), 2017 (2), 2025 (2), 2018 (1), 2023 (1), R33AR077495 (1), R61AR084210 (1)